![Merck announces positive results for KEYNOTE-756](https://oncodaily.com/pub/uploads/2023/06/Paolo-Tarantino-1-1280x1280.jpeg)
Photo from Paolo Tarantino/Twitter
Jul 30, 2023, 06:33
Merck announces positive results for KEYNOTE-756
In a post by Paolo Tarantino on Twitter, it says, “Merck announces positive results for KEYNOTE-756: the addition of pembrolizumab to neoadjuvant chemo significantly improved pCR rate among patients with high-risk HR+/HER2- breast cancer. Follow up ongoing for EFS (co-primary endpoint).”
For the article: Click here
Source:Paolo Tarantino / Twitter
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 7, 2024, 10:15